Nutrients. 2021 May 22;13(6):1770. doi: 10.3390/nu13061770.

Guillermo Bastida ¹, Claudia Herrera-de Guise ², Alicia Algaba ³, Yolanda Ber Nieto ⁴, Jose Manuel Soares ⁵, Virginia Robles ², Fernando Bermejo ³, Esteban Sáez-González ¹, Fernando Gomollón ⁶, Pilar Nos ¹

Author information

• ¹Department of Gastroenterology, CIBEREHD, Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain.
• ²Crohn-Colitis Care Unit, Vall d'Hebron Hospital Universitari, 08035 Barcelona, Spain.
• ³Department of Gastroenterology, Instituto de Investigación Sanitaria Hospital La Paz (IdiPaz), Hospital Universitario de Fuenlabrada, 28046 Madrid, Spain.
• ⁴Department of Gastroenterology, Hospital Universitario San Jorge, 22004 Huesca, Spain.
• ⁵Department of Gastroenterology, Hospital Pedro Hispano, 4454-509 Matosinhos, Portugal.

⁶IBD Unit, Digestive Diseases Service, Instituto de Investigación Sanitaria de Aragón (IIS), CIBEREHD, Hospital Clínico Universitario "Lozano Blesa", 50009 Zaragoza,

Abstract

Iron deficiency anemia (IDA) is a common manifestation of Inflammatory Bowel Disease (IBD). Oral iron supplements are the treatment of choice, but are not always well tolerated. Sucrosomial^® iron (SI) may represent an alternative. This prospective study assessed the tolerability and effectiveness of SI, and quality of life (QoL) of IDA-IBD patients who were intolerant to oral iron salts. The study included 52 individuals treated with 1 capsule/day for 12 weeks. Tolerability was assessed through a gastrointestinal symptom severity questionnaire. Hemoglobin (Hb) levels and clinical symptoms of IDA were analyzed. QoL was assessed using IBDQ-9 and EuroQoL questionnaires. The percentage of patients with excellent/good health increased from 42.9% to 94.3%. Mean Hb concentration significantly increased at all follow-up visits (p < 0.05). Almost all participants (96.9%) were adherent to the study medication. Patients' QoL improved (IBDQ-9: from 60.9 to 65.5). Patients also improved in mobility (71.8% to 78.1%), usual activities (51.3% to 68.7%), pain/discomfort (41.0% to 53.1%), and extreme depression/anxiety problems (7.7% to 3.2%); they worsened in self-care (100% to 90.6%), but perceived an enhancement in their global health [EQ-VAS score: 61.9 (±26.1) to 66.9 (±20.3)]. SI was well tolerated and improved IDA symptoms, IBD activity, and patients' QoL. In conclusion, SI should be considered in IDA-IBD patients.